By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry.

Kyntra Bio(NASDAQ:KYNB) reported that its rebranding, asset sale, and debt payoff have shifted the company’s financial structure and enabled a clinical focus on oncology and rare disease. Management ...

Proposed legislation offers perks for data centers that invest in clean energy. A broad coalition supports the bill, but ...

Today, I’m talking with Chris Cocks, CEO of Hasbro. You know, Hasbro — the toy and game company that makes some of the most ...